Amy S. Clark, MD, MSCE
Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Attending, Hospital of the University of Pennsylvania
Physician Lead, Breast Cancer Clinical Research Unit, University of Pennsylvania, Abramson Cancer Center
Medical Director, Clinical Research Unit , University of Pennsylvania, Abramson Cancer Center
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-154
3400 Civic Center Boulevard
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-154
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-662-7096
Fax: 215-615-3349
Fax: 215-615-3349
Email:
amy.clark@uphs.upenn.edu
amy.clark@uphs.upenn.edu
Education:
BS (Biology)
Haverford College, 1999.
MD (Medicine)
Milton S. Hershey Penn State College of Medicine, 2006.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2012.
Permanent linkBS (Biology)
Haverford College, 1999.
MD (Medicine)
Milton S. Hershey Penn State College of Medicine, 2006.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2012.
Description of Clinical Expertise
I am a medical oncologist who specializes in breast cancer. I only see breast cancer patients in the outpatient setting, but treat patients will all cancers when working in the hospital.Description of Research Expertise
My research focuses on clinical trials and drug development for those with early stage and metastatic breast cancer. I also seek to develop novel predictive biomarkers specifically using molecular imaging as companions to early phase trials.Selected Publications
Gitto, S. B., Pantel, A. R., Maxwell, K. N., Pryma, D. A., Farwell, M. D., Liu, F., Cao, Q., O'Brien, S. R., Clark, A. S., Shah, P. D., & McDonald, E. S.: FluorThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancer. Communications medicine Mar 2025 Notes: https://doi.org/10.1038/s43856-025-00791-0.Berlin, E., Ko, K., Ma, L., Messing, I., Hollawell, C., Smith, A. M., Taunk, N. K., Narayan, V., Upshaw, J. N., Clark, A. S., Shah, P. D., Knollman, H., Bhattacharya, S., Koropeckyj-Cox, D., Wang, J., Yegya-Raman, N., Han, I. S., Lefebvre, B., Li, T., Wilcox, N. S., Jung, W., Chen, J., Freedman, G. M., Ky, B.: Cardiac Effects of Modern Breast Radiation Therapy in Patients Receiving Systemic Cancer Therapy JACC. CardioOncology Feb 2025 Notes: https://doi.org/10.1016/j.jaccao.2025.01.012.
Clark AS, Zhao F, Klein P, Montero AJ, Falkson C, Jackson EK, Rowland K, Sardesai S, Incorvati J, Dillon P, Wolff AC, Trauger R, Heineman TC, Coffey MC, Miller KD: BRACELET-01/PrE0113: A Phase II Randomized Study of Paclitaxel (Pac), Pac/Pelareorep (Pel) or Pac/Pel/Avelumab in Metastatic Hormone Receptor Positive Breast Cancer Clinical Cancer Research 2025.
Garrido-Castro AC, Kim SE, Desrosiers J, Nanda R, Carey LA, Clark AC, Sacks RL, O’Connor TP, Sinclair NF, Steve Lo KM, Thomas A, Wrabel E, O’Meara T, Lin NU, Burstein HJ, He M, Rimm DL, Mittendorf EA, Tayob N, Tolaney SM: Correlation of TROP2 expression with outcomes of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer: an exploratory analysis from the phase II SACI-IO HR+ trial. San Antonio Texas Breast Cancer Symposium, San Antonio, TX Dec 2024.
Puhalla SL, Tang G, Swain SM, Ganz PA, Lynn Henry NL, Cecchini RS, Reid SA, Rastogi P, Geyer CE, White JR, Clark AS, Haddad TC, Vidal GA, Wolmark N, Mamounas EP: NRG-BR009: Phase III Trial Evaluating Addition of Adjuvant Chemotherapy to Ovarian Function Suppression + Endocrine Therapy in Premenopausal Women with pN0-1, HR+/HER2- Breast Cancer and Oncotype Recurrence Score ≤25 (OFSET). San Antonio Breast Cancer Symposium, San Antonio, TX. Dec 2024 Notes: "Oral Presentation"
Garrido-Castro AC, Desrosiers JA, Nanda R, Abdou YG, Clark AS, Sacks RL, O'Connor TP, Sinclair NF, Lo S, Thomas A, Wrabel E, DiLullo MK, Patel A, Rahman T, O'Meara TA, Keenan T, Dillon, DA, Lin NU, Burstein HJ, Mittendorf EA, Junkins KE, Rahee HA: Correlation of TROP2 expression with outcomes of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer: an exploratory analysis from the phase II SACI-IO HR+ trial. San Antonio Breast Cancer Symposium, San Antonio, TX December 2024.
Linden HM, Ewen D, Mankoff D, Dehdashti F, Fowler AM, Clark AS, Specht JM, Peterson LM: [18F]Fluoroestradiol (FES)-PET as a predictive measure for endocrine therapy in patients with newly diagnosed metastatic breast cancer: Results from EAI142. San Antonio Texas Breast Cancer Symposium, San Antonio, TX Dec 2024.
Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky KM, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Torres ETR, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Yi Chen Y, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood M, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van ‘t Veer LJ, Hylton NM, Esserman LJ. : Safety and efficacy of datopotamab-deruxtecan plus durvalumab in the I-SPY2.2 Sequential Multiple Assignment Randomized Trial. Nature Medicine Sep 2024 Notes: Accepted for Publication.
Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien J, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Torres ETR, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van ‘t Veer LJ, Hylton NM, Esserman LJOuthaythip, Wen Li, Natsuko Onishi, Adam L. Asare, Philip Beineke, Peter Norwood, Lamorna Brown-Swigart, Gillian L. Hirst, Jeffrey B. Matthews, Brian Moore, W. Fraser Symmans, Elissa Price, Carolyn Beedle, Jane Perlmutter, Paula Pohlmann, Rebecca A. Shatsky, Angela DeMichele, Douglas Yee, Laura J. van ‘t Veer, Nola M. Hylton, Laura J. Esserman: Datopotamab-deruxtecan in early-stage breast cancer: the phase 2 I-SPY2.2 sequential multiple assignment randomized trial. Nature Medicine Sep 2024 Notes: Accepted for Publication.
Swain S, Tang G, Puhalla SL, Ganz PA, Henry NL, Cecchini RS, Reid SA, Rastogi P, Geyer CE, White JR, Clark AS, Haddad TC, Vidal GA, Wolmark N, Mamounas EP: A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009. Journal of Clinical Oncology Jun 2024 Notes: "Poster Presentation" Meeting Abstract: 2024 ASCO Annual Meeting I.